A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C

Irritable Bowel Syndrome With Constipation (IBS-C) Clinical Trial

Official title:
A Single-Dose, Open-Label, Extension Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With Irritable Bowel Syndrome With Constipation

Status Completed

Clinical Trial Summary

A Single-Dose, Open-Label, Extension Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation

Clinical Trial Description

This is a Phase 2, multi-center, open-label study. Up to sixty subjects with irritable bowel syndrome with constipation who are between the ages of 18 and 65, inclusive, will be enrolled. Subjects must have completed the previous SB-2-010-001 study. The entire duration of the study may be up to 57 days (from enrollment to the post end-of-study [EOS] visit telephone call). ;

Study Design

Related Conditions & MeSH terms

Constipation
Irritable Bowel Syndrome
Irritable Bowel Syndrome With Constipation (IBS-C)
Syndrome

Clinical Trial Details

NCT number	NCT02493036
Study type	Interventional
Source	Synthetic Biologics Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	October 2015
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02316899` - Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome	Phase 3
Completed	`NCT03471728` - Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)
Recruiting	`NCT05643534` - Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years	Phase 3
Recruiting	`NCT05240521` - Efficacy and Safety, Tolerability of GA-AT0119 in IBS-C	N/A
Completed	`NCT02495623` - A Study of the Effect of SYN-010 on Subjects With IBS-C	Phase 2
Completed	`NCT01880424` - A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)	Phase 3
Completed	`NCT02078323` - Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients	N/A
Enrolling by invitation	`NCT05905926` - Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C	Phase 3